Skip to main content
Fig. 1 | Orphanet Journal of Rare Diseases

Fig. 1

From: Everolimus versus sirolimus for angiomyolipoma associated with tuberous sclerosis complex: a multi-institutional retrospective study in China

Fig. 1

Change in target AML volume. a Proportions of patients treated with everolimus/sirolimus with a partial response or complete clinical response in target SML lesions per physician’s global assessment at 3, 6, 12 and 24 months. b Best percentage change from baseline in the sum of volumes of target AML lesions in everolimus patients, per central radiology review. Each bar represents one patient. c Best percentage change from baseline in the sum of volumes of target angiomyolipoma lesions in sirolimus patients, per central radiology review. Each bar represents one patient

Back to article page